FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Washington, D.C. 20549

IILJ	שוור	LAC	HANG	L	
ehinaton	DC 1	205/19			

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response 0.5

## Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Thompson Peter A.					2. Issuer Name and Ticker or Trading Symbol Corvus Pharmaceuticals, Inc. [ CRVS ]								(Ch	Relationship of the control of the c	able) r		X 109	6 Owner		
(Last) (First) (Middle) C/O CORVUS PHARMACEUTICALS, INC. 863 MITTEN ROAD, SUITE 102				3. Date of Earliest Transaction (Month/Day/Year) 03/29/2016									Officer (give title Other (specify below) below)							
(Street)	(Street) BURLINGAME CA 94010				_	4. If Amendment, Date of Original Filed (Month/Day/Year)								- 1	Form filed by One Reporting Person     Form filed by More than One Reporting Person					
(City)	(5	State)	(Zip)																	
		•	Table I - N	lon-De	eriva	tive	Sec	urities A	cquire	d, D	isposed	of, or I	Bene	ficially	Owned					
Da			2. Transaction Date (Month/Day/Year)		ear)   i	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and				Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Owners (1)		
								Code	v	Amount	(A) or (D) Price		rice	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)		
Common Stock, \$0.0001 par value			03/29	03/29/2016				С		3,994,67	74 A	A .	(1)	3,994,674		I		See Footnotes <sup>(2)(3)</sup>		
Common Stock, \$0.0001 par value		03/29	03/29/2016				С		713,77	6 A	A	(1)	4,708,450		I		See Footnotes <sup>(2)(3)</sup>			
Common Stock, \$0.0001 par value			03/29	3/29/2016				<b>p</b> (5)		550,000	0 A	<b>A</b>	\$15	5,258,450		I		See Footnotes <sup>(2)(3)</sup>		
			Table I					rities Aco , warrant							Owned					
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date Execution Date or Exercise (Month/Day/Year) if any		ate, Transaction Code (Instr.		ction	5. Number of Derivative		6. Date Exercis Expiration Date (Month/Day/Ye		sable and 7. Title and Amount Securities Underlyi		ount of erlying urity	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownersl Form: Direct (Dor Indire (I) (Instr.	Beneficial Ownership ct (Instr. 4)			
				c	Code	V (A) (D)		(D)	Date Exercisa	able	Expiration Date	Title	Amount or Number of Shares		- Tran (Inst					
Series A Convertible Preferred Stock	(1)	03/29/2016			С			3,994,674	(1)		(4)	Commo: Stock	n 3,9	94,674	(1)		0	I	See Footnotes <sup>(2)(3)</sup>	
Series B Convertible	(1)	03/29/2016			С			713,776	(1)		(4)	Commo	n 71	13,776	(1)		0	I	See	

## **Explanation of Responses:**

Stock

- 1. The Series A Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis at the consummation of the Issuer's initial public offering.
- 2. These securities are held of record by OrbiMed Private Investments V, LP ("OPI V"). OrbiMed Capital GP V LLC ("GP V") is the sole general partner of OPI V, and OrbiMed Advisors LLC ("Advisors"), a registered adviser under the Investment Advisers Act of 1940, as amended, is the sole managing member of GP V. Samuel D. Isaly ("Isaly"), a natural person, is the managing member of, and holder of a controlling interest in, Advisors. By virtue of such relationships, GP V, Advisors and Isaly may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is an employee of Advisors.
- 3. Each of GP V, Advisors, Isaly and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
- 4. The expiration date is not relevant to the conversion of these securities.
- 5. OPI V purchased an additional 550,000 shares of the Issuer's common stock in connection with the Issuer's initial public offering at the offering price of \$15.00 per share.

/s/ Leiv Lea, as Attorney-in-Fact 03/29/2016 for Peter A. Thompson

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.